Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

BERKELEY, US – MAINZ, Germany – DECEMBER 12, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation.

The first attended conference, the 17th Conference: Advances in Gastroenterology, ran from December 8th to 9th, 2023, in Poznań. This national event brought together over 200 attendees, comprising healthcare specialists, patient advocates, and policymakers. Mainz Biomed and TestDNA collaborated to showcase ColoAlert® the Company’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) and provide valuable insights from the forefront of diagnostic innovation.

Following this, Mainz Biomed will be taking part in the 10th Gdańsk Gastroenterology Symposium which runs from January 12th to 13th, 2024. The symposium will gather national Polish lecturers, scientists, and practitioners who will collectively share the latest insights in gastroenterology, hepatology, and gastrointestinal endoscopy.

At the symposium, Mr. Steve Quinn, VP of International Business Development at Mainz Biomed, will open the agenda with a presentation titled 'Colorectal Cancer - The Need for Earlier Detection.' The presentation will underscore Mainz Biomed's commitment to advocating for early detection strategies in combating colorectal cancer and its dedication to advancing the landscape of gastroenterological diagnostics.

Darin Leigh, Chief Commercial Officer of Mainz Biomed, expressed enthusiasm about the upcoming conferences, stating, "Our collaboration with TestDNA at these prestigious conferences is a testament to our shared commitment to revolutionize CRC detection and improve patient outcomes. We are always thrilled to engage with leading experts and practitioners to explore innovative strategies in gastroenterology. With over 21 million people aged over 40, the market opportunity for ColoAlert® in Poland is significant, especially as there has been a low level of national participation in CRC screening which traditionally has been colonoscopies."

Please follow us to stay up to date:

About Mainz Biomed NV 

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit.

For media inquiries -

In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
20

In the U.S.:
Josh Stanbury

For investor inquiries, please contact

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company’s SEC filings are available publicly on the SEC’s website at Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.